智通财经APP讯，康希诺生物(06185)发布公告，于2025年11月27日，该公司注销40.61万股已回购股 份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 688185 | 說明 | A 股 (上海證券交易所科創版) | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年10月31日 | | 114,372,901 | | 406,098 | | 114,778,999 | | 1). 註銷庫存股份 | | | | % ...

登录新浪财经APP 搜索【信披】查看更多考评等级 二、本次回购A股股份的注销情况 1、本次回购A股股份注销的原因及依据 根据《中华人民共和国公司法》《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7号一回购股份》，以及《康希诺生物股份公司章程》等相关法律、法规及规范性文件规定，对于回购 股份用于员工持股或股权激励的，应当在回购实施完成后三年内按照依法披露的用途进行转让，未按照 披露用途转让的，应当在三年期限届满前注销。 鉴于公司在三年期限届满前未将全部回购股份用于员工持股计划或股权激励，公司将对回购专用证券账 户中对应的406,098股股票全部予以注销，并相应减少公司注册资本。 ● 注销后公司股本结构变化：本次回购股份注销后，公司总股本将由目前的247,449,899股（其中A股 114,778,999股，H股132,670,900股）相应减少至247,043,801股（其中A股114,372,901股，H股 132,670,900股）。 一、本次回购A股股份注销的决策与信息披露 康希诺生物股份公司（以下简称"公司"、"康希诺"）于2025年9月26日召开了第三届董事会第二次临时 会议和第三届 ...

Focus 1: Jianlong Micro-Nano (688357) - The company has terminated the planning of a major asset restructuring, which was intended to acquire at least 51% of Shanghai Hanxing Energy Technology Co., Ltd. through cash payment for equity [1] Focus 2: Industrial Fulian - The company has adjusted the maximum repurchase price for its shares from 19.36 yuan per share to 75.00 yuan per share, reflecting confidence in its future development and market conditions [2] Focus 3: *ST Dongtong - The company received a prior notice from the Shenzhen Stock Exchange regarding the proposed termination of its stock listing [3] Focus 4: Fundraising & Restructuring - Aolaide plans to raise up to 299.71 million yuan through a simplified procedure for issuing shares to specific targets, with proceeds allocated for OLED display core material production and working capital [4] - Maigemi has received approval from the Shenzhen Stock Exchange for its application to issue shares to specific targets, meeting all necessary conditions [4] - Su Yan Jingshen has also received approval for its share issuance application, pending final registration with the China Securities Regulatory Commission [4] Focus 5: Important Matters - Baiao Chemical's major shareholders are transferring a total of 10% of the company's shares to Liu Hongjun, resulting in him holding 10% of the total share capital post-transfer [5][6] - Zhejiang Pharmaceutical is planning to spin off its subsidiary for a listing on the Hong Kong Stock Exchange, which will not affect its control over the subsidiary [6] - Huafeng Aluminum is acquiring 100% of Shanghai Huafeng Puen Polyurethane Co., Ltd. for 100.06 million yuan, which will enhance its operational efficiency and market competitiveness [7] Focus 6: New Investments - Fuda Co. is establishing a wholly-owned subsidiary with an investment of 30 million yuan to enhance its forging business and related manufacturing capabilities [8] - Jianghai Co. is forming a joint venture to establish an innovation research institute with a registered capital of 50 million yuan, focusing on strategic technology research [9][10] Focus 7: Capital Market Activities - Zhongshan Bank has issued 60 billion yuan of subordinated debt with a fixed interest rate of 2.16% for a term of 10 years [17] - China Iron and Steel Group plans to increase its stake in China Iron and Steel Co. by investing between 65 million and 130 million yuan over the next six months [18]

Core Insights - The price war in the vaccine industry is driven by changes in supply and demand dynamics, leading to significant price reductions and financial losses for companies [2][10][15] Group 1: Price Trends - The price of a three-valent flu vaccine has dropped to 5.5 yuan, lower than the price of a cup of milk tea, indicating a drastic reduction in vaccine prices [3][7] - The price of the four-valent flu vaccine has decreased from 128 yuan to 88 yuan, with further reductions expected as competition intensifies [7][8] - HPV vaccines have also seen significant price drops, with the two-valent HPV vaccine priced at 27.5 yuan, down over 90% from previous prices [8] Group 2: Industry Response - The China Vaccine Industry Association issued an initiative to combat "involutionary" competition, urging members to avoid bidding below cost and maintain price stability [4][5] - The association's initiative aims to stabilize price expectations but may not address the underlying issue of overcapacity in the industry [3][10] Group 3: Market Dynamics - The vaccine market is experiencing overcapacity due to an influx of companies entering the sector, leading to intense competition and price wars [10][11] - Demand for vaccines is under pressure, with declining public trust in vaccines and a decrease in birth rates affecting the market for childhood vaccines [11][12] Group 4: Financial Impact - Vaccine companies have reported significant financial losses, with overall revenue for listed vaccine companies dropping by 60% and net profits declining by 113% in the first half of 2025 [12][14] - Major companies like Zhifei Biological and Wantai Biological have reported substantial revenue declines and net losses, reflecting the severe impact of the price war [12][14] Group 5: Future Outlook - Experts suggest that the industry may need to undergo a period of consolidation and restructuring, which could last five to ten years, to address the current challenges [15] - Companies are exploring international markets and differentiation strategies to navigate the competitive landscape, with some reporting significant increases in exports [15]

Core Points - The company, CanSino, announced a share repurchase with a cancellation date set for November 27, 2025 [1] - A total of 406,098 A-shares will be canceled as part of this repurchase [1]

Core Viewpoint - The article discusses the ongoing price war in China's vaccine industry, driven by changes in supply and demand dynamics, leading to significant price reductions and financial losses for companies [4][15][22]. Group 1: Price War Dynamics - The price of a three-valent flu vaccine has dropped to 5.5 yuan, cheaper than a cup of milk tea, indicating a severe price competition in the vaccine market [5][11]. - The China Vaccine Industry Association has issued an initiative to combat "involution-style" competition, urging members to avoid bidding below cost and threatening penalties for violations [6][8][10]. - The price war has persisted for two years, with the association's initiative being the first formal stance against low-price competition, although it may not resolve the underlying issue of overcapacity [6][10][22]. Group 2: Supply and Demand Changes - The supply side is characterized by homogenization and overcapacity, with many companies entering the vaccine market, leading to intense competition and price wars [16][17]. - Demand is also under pressure, with declining public trust in vaccines and a decrease in vaccination rates, particularly for flu vaccines, which averaged below 4% in China from 2020 to 2023 [17][19]. - The shift in focus from childhood vaccines to adult vaccines due to declining birth rates has intensified competition in the adult vaccine market [17][19]. Group 3: Financial Impact on Companies - The financial repercussions of the price war are evident, with vaccine companies experiencing a 60% drop in revenue and a 113% decline in net profit in the first half of 2025 [19][20]. - Major companies like Zhifei Biological and Wantai Biological have reported significant losses, with Zhifei's revenue down 66.53% and net profit loss of 12.06 billion yuan [20][21]. - Despite some companies showing growth in sales, the overall trend indicates that increased revenue does not equate to increased profit due to drastic price reductions [21][22]. Group 4: Future Outlook and Strategies - Experts suggest that the industry is in a "deep cold moment," requiring a period of consolidation and restructuring that could last five to ten years [23]. - Companies are exploring two main strategies to navigate the competitive landscape: expanding into emerging markets and focusing on differentiated products to meet unmet clinical needs [24].

Core Viewpoint - 康希诺生物 announced the cancellation of 406,100 shares from its repurchase account due to non-compliance with the intended use for employee stock ownership or equity incentives within the stipulated three-year period [1] Group 1: Company Actions - 康希诺生物's share repurchase was governed by relevant laws and regulations, including the Company Law of the People's Republic of China and the Shanghai Stock Exchange's guidelines [1] - The company is required to transfer repurchased shares for employee stock ownership or equity incentives within three years of repurchase [1] - As the company did not utilize all repurchased shares for the intended purposes, it will cancel the 406,100 shares and reduce its registered capital accordingly [1]

Core Viewpoint - 康希诺生物 announced the cancellation of 406,100 shares from its repurchase account due to non-compliance with the intended use for employee stock ownership or equity incentives within the stipulated three-year period [1] Group 1: Regulatory Compliance - The company is adhering to the regulations set forth by the Company Law of the People's Republic of China and the relevant rules for share repurchase [1] - According to the guidelines, shares repurchased for employee stock ownership or equity incentives must be transferred within three years of repurchase [1] Group 2: Share Cancellation - 康希诺生物 will cancel all 406,100 shares that were not utilized for the intended purposes, leading to a corresponding reduction in the company's registered capital [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 海外監管公告 本 公 告 乃 康 希 諾 生 物 股 份 公 司（「本公司」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市規則第13.10B條而發表。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 發 的《康 希 諾 生 物 股 份 公 司 關 於 回 購A股 股 份 註 銷 實 施 的 公 告》，僅 供 參 閱。 承董事會命 康希諾生物股份公司 Xuefeng YU 董事長 香港，2025年11月26日 於 本 公 告 日 期，本 公 司 董 事 會 包 括 執 行 董 事Xuefeng YU博 士、Shou Bai CHAO博 士及王靖女士；非執行董事李志成先生；以及獨立非執行董事桂水發先生、劉建 忠先生及張耀樑先生。 证券 ...